CA
NZ
UK
AU
IND
US
…
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Korro Bio, Inc. develops circular RNA (icRNA) therapeutics and vaccines that aim to produce more stable, durable protein expression than linear mRNA; its platform targets infectious disease and therapeutic protein delivery. Long-term growth drivers include broader adoption of RNA modalities, platform expansion across indications, and potential scalability of manufacturing, which could make it attractive to investors seeking exposure to next-generation RNA technologies.
The primary investment risk is that the platform remains early-stage with limited clinical validation and will require successful clinical, regulatory outcomes and additional financing to reach commercial viability.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -116.62M | -83.44M | -81.14M | -58.02M | -21.96M |
| Net income | -117.26M | -83.58M | -81.17M | -58.03M | -21.96M |
| Selling general administrative | 28.16M | 30.55M | 27.28M | 16.80M | 11.69M |
| Gross profit | 2.11M | 2.27M | -3.63M | -2.51M | 10.23M |
| Reconciled depreciation | 4.28M | 3.56M | 3.63M | 2.51M | 1.59M |
| Ebit | -87.34M | -91.91M | -84.53M | -59.00M | -35.49M |
| Ebitda | -83.06M | -88.34M | -80.90M | -56.49M | -33.90M |
| Depreciation and amortization | 4.28M | 3.56M | 3.63M | 2.51M | 1.59M |
| Operating income | -87.34M | -91.91M | -84.53M | -59.00M | -35.49M |
| Other operating expenses | 93.73M | 94.18M | 84.53M | 59.00M | 35.49M |
| Interest expense | - | - | - | 0.12M | - |
| Tax provision | 0.64M | 0.14M | 0.03M | 0.01M | 0.00M |
| Interest income | - | - | - | 0.95M | - |
| Net interest income | - | - | - | 0.83M | - |
| Income tax expense | 0.64M | 0.14M | 0.03M | 0.01M | 0.00M |
| Total revenue | 6.39M | 2.27M | 0.00M | 0.00M | 14.07M |
| Total operating expenses | 89.45M | 94.18M | 84.53M | 59.00M | 35.49M |
| Cost of revenue | 4.28M | 3.56M | 3.63M | 2.51M | 3.84M |
| Total other income expense net | -29.28M | 8.47M | 3.39M | 0.98M | 13.54M |
| Net income from continuing ops | -117.26M | -83.58M | -81.17M | -58.03M | -21.96M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 113.51M | 226.24M | 221.66M | 73.74M | 127.58M |
| Other current assets | 6.25M | 3.74M | 3.02M | 1.83M | 1.24M |
| Total liab | 62.07M | 65.83M | 51.75M | 172.77M | 169.78M |
| Total stockholder equity | 51.44M | 160.41M | 169.91M | -99.03M | -42.21M |
| Other current liab | -0.22M | 6.17M | 0.84M | 0.28M | 0.50M |
| Common stock | 0.01M | 0.01M | 0.01M | - | - |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -383.85M | -266.59M | -183.00M | -101.83M | -43.80M |
| Cash | 21.82M | 55.64M | 166.15M | 36.33M | 83.49M |
| Total current liabilities | 11.94M | 14.96M | 19.48M | 8.70M | 4.95M |
| Current deferred revenue | 7.83M | 3.51M | 9.37M | - | - |
| Net debt | 21.66M | -10.88M | -132.94M | - | - |
| Short term debt | 2.67M | 1.28M | 1.99M | - | - |
| Short long term debt total | 43.49M | 44.77M | 33.21M | - | - |
| Other stockholder equity | 435.06M | 426.72M | 352.91M | - | - |
| Total current assets | 82.37M | 131.53M | 172.73M | 57.08M | 119.78M |
| Long term investments | 10.03M | 36.96M | - | - | - |
| Short term investments | 53.33M | 70.45M | 0.00M | 18.91M | 35.04M |
| Net receivables | 0.97M | 1.70M | - | - | - |
| Accounts payable | 1.65M | 3.99M | 7.28M | 2.60M | 0.79M |
| Accumulated other comprehensive income | 0.21M | 0.27M | 0.00M | - | - |
| Non currrent assets other | 0.27M | 6.20M | 2.71M | 4.69M | 0.66M |
| Non current assets total | 31.13M | 94.71M | 48.94M | 16.66M | 7.80M |
| Capital lease obligations | 43.49M | 44.77M | 33.21M | 3.13M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 44.51M | -123.35M | 11.16M | 11.06M | -39.50M |
| Total cashflows from investing activities | 43.99M | -123.35M | - | - | - |
| Total cash from financing activities | 0.69M | 69.36M | 187.76M | 0.02M | 115.94M |
| Net income | -117.26M | -83.58M | -81.17M | -58.03M | -21.96M |
| Change in cash | -33.82M | -114.07M | 131.64M | -42.57M | 44.35M |
| Begin period cash flow | 59.05M | 173.12M | 41.48M | 84.04M | 39.69M |
| End period cash flow | 25.23M | 59.05M | 173.12M | 41.48M | 84.04M |
| Total cash from operating activities | -78.56M | -60.07M | -67.28M | -53.65M | -32.09M |
| Issuance of capital stock | 0.00M | 67.39M | 162.71M | 0.00M | 115.95M |
| Depreciation | 3.79M | 3.56M | 3.63M | 2.51M | 1.59M |
| Change to account receivables | 0.73M | -1.70M | - | - | - |
| Other cashflows from financing activities | 0.69M | 1.97M | 24.35M | -0.04M | -0.03M |
| Capital expenditures | 0.52M | 17.90M | 7.84M | 5.21M | 4.45M |
| Change in working capital | -4.43M | 13.59M | 4.28M | -0.63M | 0.90M |
| Stock based compensation | 7.66M | 4.46M | 2.38M | 1.14M | 0.81M |
| Other non cash items | 31.68M | 1.89M | 3.61M | 1.51M | -13.47M |
| Free cash flow | -79.08M | -77.98M | -75.12M | -58.86M | -36.54M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| KRRO Korro Bio, Inc. |
0.12 0.81% |
14.31 | - | - | 86.98 | 1.99 | 55.61 | -5.60 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Nessan Bermingham Ph.D. | Co-Founder & Executive Chairman | 1973 |
| Mr. Ram Aiyar MBA, Ph.D. | CEO, President & Director | 1978 |
| Dr. Jean-Francois Formela M.D., MBA | Co-Founder & Director | 1957 |
| Mr. Vineet Agarwal M.B.A. | Chief Financial Officer | 1982 |
| Dr. Steven L. Colletti Ph.D. | Chief Scientific Officer | 1966 |
| Mr. Andrew Fraley Ph.D. | Co-Founder & CTO | NA |
| Mr. Josh Rosenthal Ph.D. | Co-Founder & Advisor | NA |
| Mr. Todd Chappell | Chief Operating Officer | 1973 |
| Ms. Shelby Walker J.D. | Senior VP & General Counsel | 1975 |
| Mr. Ravi Ramadas Ph.D. | Vice President of Business & Corporate Development | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...